LCS
PACB icon

Levin Capital Strategies’s Pacific Biosciences PACB Stock Holding History

Levin Capital Strategies’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,043,709
Closed -$3.97M – 326
2016
Q4 		$3.97M Buy
1,043,709
+894,627
+600% +$6.5M 0.07% 100
2016
Q3 		$1.34K Sell
149,082
-49,518
-25% -$414K 0.02% 156
2016
Q2 		$1.4M Sell
198,600
-29,300
-13% -$268K 0.03% 152
2016
Q1 		$1.94M Buy
227,900
+170,400
+296% +$1.68M 0.04% 144
2015
Q4 		$755K Buy
+57,500
New +$516K 0.01% 221

Other funds holding PACB

Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Levin Capital Strategies's PACB Position: Q1 2017 in Review

Levin Capital Strategies sold out of Pacific Biosciences (PACB) in Q1 2017, closing a stake of 1,043,709 shares — an estimated $3.97M sold.

Levin Capital Strategies first reported a position in PACB in Q4 2015 and held it in 5 quarters. The position peaked at $3.97M in Q4 2016. 106 funds tracked by Wall St. Rank hold PACB as of Q1 2017.

  • Levin Capital Strategies reported no remaining Pacific Biosciences position as of Q1 2017 after selling out during the quarter.
  • Levin Capital Strategies sold 1,043,709 Pacific Biosciences shares in Q1 2017, an estimated $3.97M.
  • Levin Capital Strategies first reported a position in Pacific Biosciences in Q4 2015 and held it in 5 quarters.
  • Levin Capital Strategies's Pacific Biosciences position peaked at $3.97M in Q4 2016.
  • 106 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2017.

Based on Levin Capital Strategies's 13F filing for Q1 2017, filed 9 May 2017.